Michela Buglione

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5021819/publications.pdf

Version: 2024-02-01

218592 2,603 114 26 citations h-index papers

g-index 114 114 114 4170 docs citations times ranked citing authors all docs

214721

47

#	Article	IF	CITATIONS
1	Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. Journal of Clinical Oncology, 2016, 34, 427-435.	0.8	203
2	Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. British Journal of Cancer, 2017, 116, 1520-1525.	2.9	121
3	Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1NO disease. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1378-1386.	0.4	114
4	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements Critical Reviews in Oncology/Hematology, 2016, 100, 147-166.	2.0	112
5	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 372-384.	2.0	95
6	Circulating Tumour Cells in locally advanced head and neck cancer: Preliminary report about their possible role in predicting response to non-surgical treatment and survival. European Journal of Cancer, 2012, 48, 3019-3026.	1.3	92
7	Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature. Cancers, 2019, 11, 1284.	1.7	90
8	Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2NO disease. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1387-1394.	0.4	88
9	Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiotherapy and Oncology, 2011, 99, 356-361.	0.3	83
10	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 97, 131-142.	2.0	82
11	Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007. Neurosurgery, 2010, 67, 446-458.	0.6	73
12	Circulating Tumor Cells in Patients with Recurrent or Metastatic Head and Neck Carcinoma: Prognostic and Predictive Significance. PLoS ONE, 2014, 9, e103918.	1.1	69
13	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World Journal of Urology, 2019, 37, 2631-2637.	1.2	69
14	Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro-Oncology, 2013, 15, 618-625.	0.6	64
15	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 102, 47-54.	2.0	51
16	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 167-182.	2.0	46
17	HERâ€2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinicoâ€pathologic study. Journal of Cellular and Molecular Medicine, 2009, 13, 3826-3833.	1.6	44
18	COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiotherapy and Oncology, 2020, 149, 89-93.	0.3	43

#	Article	IF	CITATIONS
19	EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide. Journal of the National Cancer Institute, 2015, 107, .	3.0	39
20	Correlation between Human Papillomavirus Status and Quantitative MR Imaging Parameters including Diffusion-Weighted Imaging and Texture Features in Oropharyngeal Carcinoma. American Journal of Neuroradiology, 2018, 39, 1878-1883.	1.2	39
21	Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 462-472.	0.4	35
22	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 95, 191-213.	2.0	33
23	Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. Oral Oncology, 2021, 115, 105213.	0.8	33
24	Surgery in cerebral metastases: Are numbers so important?. Journal of Cancer Research and Therapeutics, 2014, 10, 79.	0.3	28
25	Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1077-1083.	0.4	28
26	Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions. British Journal of Radiology, 2016, 89, 20150981.	1.0	27
27	A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients. Scientific Reports, 2020, 10, 13589.	1.6	27
28	Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice. Radiologia Medica, 2021, 126, 142-146.	4.7	27
29	Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro-Oncology, 2012, 14, 798-807.	0.6	26
30	Salvage therapy of small volume prostate cancer nodal failures: A review of the literature. Critical Reviews in Oncology/Hematology, 2014, 90, 24-35.	2.0	25
31	Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. International Journal of Radiation Oncology Biology Physics, 2006, 65, 788-799.	0.4	23
32	Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: A case report and review of literature. Journal of Medical Case Reports, 2008, 2, 320.	0.4	22
33	Reirradiation in Head and Neck Recurrent or Second Primary Tumor: Efficacy, Safety, and Prognostic Factors. Tumori, 2015, 101, 585-592.	0.6	22
34	Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature. Journal of Neurosurgical Sciences, 2019, 63, 458-467.	0.3	22
35	Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed?. Journal of Neuro-Oncology, 2016, 128, 303-312.	1.4	21
36	MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer. Cancers, 2021, 13, 1791.	1.7	21

#	Article	IF	CITATIONS
37	The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications. Reports of Practical Oncology and Radiotherapy, 2014, 19, 77-91.	0.3	20
38	Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). Radiologia Medica, 2018, 123, 48-62.	4.7	20
39	Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR) Tj ETQq1 1 0.78	4 3)16 rgBT	/20verlock
40	Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum. Radiation Oncology, 2020, 15, 62.	1.2	20
41	Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative―intent. Lung Cancer, 2020, 141, 1-8.	0.9	17
42	Cetuximab and Radiation Therapy Versus Cisplatin and Radiation Therapy for Locally Advanced Head and Neck Cancer: Long-Term Survival and Toxicity Outcomes of a Randomized Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2020, 107, 469-477.	0.4	17
43	Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets. Cancers, 2021, 13, 2527.	1.7	17
44	Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative program. Reports of Practical Oncology and Radiotherapy, 2015, 20, 284-291.	0.3	16
45	The STYRO 2011 project: a survey on perceived quality of training among young Italian radiation oncologists. Medical Oncology, 2013, 30, 729.	1.2	15
46	Whole brain radiotherapy with adjuvant or concomitant boost in brain metastasis: dosimetric comparison between helical and volumetric IMRT technique. Radiation Oncology, 2016, 11, 59.	1.2	15
47	Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncology, The, 2017, 18, e379-e393.	5.1	15
48	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Advances, 2021, 5, 4504-4514.	2.5	14
49	Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience. In Vivo, 2018, 32, 159-164.	0.6	14
50	Interobserver variability in clinical target volume delineation for primary mediastinal B-cell lymphoma. Practical Radiation Oncology, 2015, 5, 383-389.	1.1	13
51	Postoperative radiotherapy for prostate cancer: the sooner the better and potential to reduce toxicity even further. Radiologia Medica, 2018, 123, 63-70.	4.7	13
52	Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab. Clinical Lung Cancer, 2020, 21, e547-e550.	1.1	13
53	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. European Journal of Cancer, 2021, 159, 194-204.	1.3	13
54	Post-ABVD/pre-radiotherapy < sup > 18 < / sup > F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. British Journal of Radiology, 2016, 89, 20150983.	1.0	12

#	Article	IF	CITATIONS
55	Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease. Critical Reviews in Oncology/Hematology, 2017, 117, 48-56.	2.0	12
56	A simplified integrated molecular and immunohistochemistry-based algorithm allows high accuracy prediction of glioblastoma transcriptional subtypes. Laboratory Investigation, 2020, 100, 1330-1344.	1.7	12
57	Radiotherapy in low-grade glioma adult patients: a retrospective survival and neurocognitive toxicity analysis. Radiologia Medica, 2014, 119, 432-439.	4.7	11
58	Light and shadows of a new technique: isÂphoton total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one?. Radiation Oncology, 2018, 13, 158.	1.2	11
59	Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. Radiologia Medica, 2019, 124, 315-322.	4.7	11
60	Could Concomitant Radio-Chemotherapy Improve the Outcomes of Early-Stage Node Negative Anal Canal Cancer Patients? A Retrospective Analysis of 122 Patients. Cancer Investigation, 2015, 33, 114-120.	0.6	10
61	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq1 1 Reviews in Oncology/Hematology, 2019, 134, 104-119.	0.784314 2.0	rgBT /Overlo
62	Retreatment of recurrent adult medulloblastoma with radiotherapy: a case report and review of the literature. Journal of Medical Case Reports, 2013, 7, 64.	0.4	9
63	Two months of radiation oncology in the heart of Italian "red zone―during COVID-19 pandemic: paving a safe path over thin ice. Radiation Oncology, 2020, 15, 191.	1.2	9
64	Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic. Radiotherapy and Oncology, 2020, 147, 229-230.	0.3	9
65	A Systematic Review on Intensity Modulated Radiation Therapy for Mediastinal Hodgkin's Lymphoma. Critical Reviews in Oncology/Hematology, 2021, 167, 103437.	2.0	9
66	The treatment of patients with 1–3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis. Radiologia Medica, 2015, 120, 1146-1152.	4.7	8
67	Clinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage III and IV disease. Radiologia Medica, 2016, 121, 70-79.	4.7	8
68	Exploring the Role of Enzalutamide in Combination with Radiation Therapy: An <i>In Vitro</i> Study. Anticancer Research, 2018, 38, 3487-3492.	0.5	8
69	Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR). PLoS ONE, 2019, 14, e0224151.	1.1	8
70	Three-dimensional conformal radiotherapy, static intensity-modulated and helical intensity-modulated radiotherapy in glioblastoma. Dosimetric comparison in patients with overlap between target volumes and organs at risk. Tumori, 2014, 100, 272-7.	0.6	8
71	Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature. Anticancer Research, 2016, 36, 2975-81.	0.5	8
72	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq0 0 0 Reviews in Oncology/Hematology, 2019, 134, 87-103.	0 rgBT /Ov 2.0	verlock 10 Tf 5 7

Reviews in Oncology/Hematology, 2019, 134, 87-103.

#	Article	IF	CITATIONS
73	Changes in Patterns of Practice for Prostate Cancer Radiotherapy in Italy 1995–2003. A Survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society. Tumori, 2014, 100, 31-37.	0.6	7
74	External Beam Radiotherapy $\hat{A}\pm$ Chemotherapy in the Treatment of Anal Canal Cancer: A Single-Institute Long-Term Experience on 100 Patients. Cancer Investigation, 2014, 32, 248-255.	0.6	6
75	Reliability of prostate-specific antigen-marker in determining biochemical failure during the first 2 years after external beam radiation therapy and hormone therapy in patients with non-operated prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e1-30.e7.	0.8	6
76	Clinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage I and II disease. Radiologia Medica, 2015, 120, 1071-1077.	4.7	6
77	Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. Journal of Neuro-Oncology, 2019, 143, 447-455.	1.4	6
78	Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society. Tumori, 2014, 100, 31-7.	0.6	6
79	Predictive factors for oropharyngeal mycosis during radiochemotherapy for head and neck carcinoma and consequences on treatment duration. Results of mycosis in radiotherapy (MIR): A prospective longitudinal study. Radiotherapy and Oncology, 2013, 109, 303-310.	0.3	5
80	Overexpression of sialidase NEU3 increases the cellular radioresistance potential of U87MG glioblastoma cells. Biochemical and Biophysical Research Communications, 2019, 508, 31-36.	1.0	5
81	The linguistic validation process of the Vanderbilt Head and Neck Symptom Survey - Italian Version (VHNSS-IT). Radiologia Medica, 2020, 125, 228-235.	4.7	5
82	COVID-19 safe and fully operational radiotherapy: An AIRO survey depicting the Italian landscape at the dawn of phase 2. Radiotherapy and Oncology, 2021, 155, 120-122.	0.3	5
83	Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1773-1779.	1.2	5
84	Impact of Gastrointestinal Side Effects on Patients' Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study. Cancers, 2021, 13, 1479.	1.7	5
85	â€~Le Roi est mort, vive le Roi': new roles of radiotherapy in the treatment of lymphomas in combination with immunotherapy Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	5
86	Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy. Radiologia Medica, 2016, 121, 696-703.	4.7	4
87	A pilot study on the Vanderbilt head and neck symptom survey Italian version (VHNSS-IT) to test its feasibility and utility in routine clinical practice. Radiologia Medica, 2020, 125, 423-431.	4.7	4
88	Non-metastatic ductal adenocarcinoma of the prostate: pattern of care from an uro-oncology multidisciplinary group. World Journal of Urology, 2021, 39, 1161-1170.	1.2	4
89	Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients. Radiation Oncology, 2021, 16, 239.	1.2	4
90	Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines. Tumori, 2018, 104, 394-400.	0.6	3

#	Article	IF	CITATIONS
91	A Neuro-Oncologic Challenge: The Case of a Large, Aggressive, Malignant Meningioma of the Skull Base with Paranasal Sinus Involvement. Tumori, 2016, 102, S5-S8.	0.6	2
92	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. Leukemia and Lymphoma, 2016, 57, 2677-2680.	0.6	2
93	Cetuximab and Radiation Therapy in Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 678-679.	0.4	2
94	Letter to the editor regarding "Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable― Radiotherapy and Oncology, 2020, 150, 172-173.	0.3	2
95	Prevention and management of acute esophageal toxicity during concomitant chemoradiotherapy for locally advanced lung cancer. Tumori, 2022, 108, 470-476.	0.6	2
96	Universal testing for COVID-19 in patients undergoing cancer treatment during the second outbreak in Brescia. Tumori, 2021, , 030089162110349.	0.6	2
97	Advanced Radiotherapy Techniques for Mediastinal Lymphomas: Results from an Italian Survey. Hemato, 2021, 2, 496-504.	0.2	2
98	Exploiting Machine Learning for Predicting Nodal Status in Prostate Cancer Patients. IFIP Advances in Information and Communication Technology, 2013, , 61-70.	0.5	2
99	Optimizing Radiation Treatment Decisions for Patients Who Receive Neoadjuvant Chemotherapy. Journal of the National Cancer Institute Monographs, 2015, 2015, 9-10.	0.9	1
100	Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial― resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group. Radiologia Medica, 2015, 120, 975-981.	4.7	1
101	Radiation Tolerance of Normal Brain: QUANTEC 2010 and Beyond. Current Clinical Pathology, 2016, , 121-135.	0.0	1
102	Selection of systemic therapy in patients with locally advanced and recurrent/metastatic head and neck cancer: RAND-based expert opinion by an Italian multidisciplinary panel. Tumori, 2020, 106, 177-189.	0.6	1
103	Letter to "Medial lingual lymph node metastasis in carcinoma of the tongue― Auris Nasus Larynx, 2020, 47, 1091-1092.	0.5	1
104	In reply to Simcock et al Clinical and Translational Radiation Oncology, 2020, 23, 65.	0.9	1
105	RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment. Cancers, 2022, 14, 2273.	1.7	1
106	In reply to Borras et al. The strengthening of Radiation Oncologist role inside multidisciplinary arena within 2025. Radiotherapy and Oncology, 2016, 119, 369.	0.3	0
107	From Molecular to Clinical Radiation Biology of Glioblastoma. Current Clinical Pathology, 2016, , 275-292.	0.0	0
108	The "Radioresistance―of Glioblastoma in the Clinical Setting, and the Present Therapeutic Options. Current Clinical Pathology, 2016, , 15-27.	0.0	0

#	Article	IF	CITATIONS
109	The growing role of biology in the treatment of glioblastoma: no more one kind of disease. Journal of Neuro-Oncology, 2017, 133, 211-212.	1.4	O
110	Reply to â€~Comment on â€~Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study''. British Journal of Cancer, 2018, 118, e2-e2.	2.9	0
111	Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists. Tumori, 2018, 104, 466-470.	0.6	0
112	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	1.2	0
113	Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Journal of Cancer Research and Clinical Oncology, 2021, 147, 793-802.	1.2	O
114	Clinical and pathological prognostic factors in Merkel cell carcinoma Journal of Clinical Oncology, 2022, 40, e21574-e21574.	0.8	0